Abstract. Clear cell renal cell carcinoma (ccRCC) is one of the most common types of kidney cancer and is accompanied by a poor prognosis due to a high potential for metastasis and recurrence. The mechanism of ccRCC metastasis is not well known. N-lysine methyltransferase KMT5A serves a crucial role in the progression of human cancer; however, the function of KMT5A in the development of ccRCCs has not yet been investigated, which has triggered an interest in investigating the potential association between KMT5A and ccRCC. The present study demonstrates for the first time that KMT5A is a driving factor in ccRCC metastasis. The KMT5A expression level was revealed to be significantly higher in ccRCC tissues compared with adjacent normal tissues. Patients with ccRCC whose tumors expressed high levels of KMT5A were demonstrated to have significantly shorter postoperative survival times. In vitro knockdown of KMT5A expression in 786-O cells inhibited cell migration and invasion. KMT5A reduced cadherin-1 (CDH1) protein levels by directly inhibiting its transcription. The CDH1 mRNA levels were inversely correlated with KMT5A expression in ccRCC samples. Patients with high tumor KMT5A or low CDH1 levels had the poorest prognosis with the shortest overall survival (OS) time, and this combination was demonstrated to be an independent prognostic indicator for patient OS time in ccRCC, more accurate than monitoring KMT5A or CDH1 alone. Together, these results indicate that KMT5A serves a vital role in ccRCC development and progression, and it may be a novel target for ccRCC treatment and prevention.
Introduction
Renal cell carcinoma (RCC) arises mainly in the renal parenchyma, and accounts for >90% of kidney carcinomas worldwide (1) . RCC has the highest mortality rate among the types of genitourinary cancer with cancer statistics for 2018 indicating that RCC constitutes 3% of adult malignant tumors and accounts for 2% of all cancer mortalities (2) . A significant histological subtype of RCC is clear cell (cc)RCC. Although the treatment method of nephrectomy has improved survival times, advanced ccRCC remains lethal due to tumor metastasis and recurrence (3) . Furthermore, the pathogenesis of ccRCC is not well understood and the underlying genetic defects are widespread and complex. The molecular mechanism of ccRCC tumor growth and metastasis is also unclear and its clarification will accelerate the identification of novel targets for treatment and intervention.
N-lysine methyltransferase KMT5A, a member of the SET domain-containing methyltransferase family, specifically catalyzes the monomethylation of histone H4 lysine 20 (4, 5) . KMT5A helps maintain genome integrity and regulates cell cycle progression and development (6) (7) (8) (9) (10) (11) . Previous studies have reported that KMT5A is overexpressed in several tumors, including hepatocellular carcinoma, breast cancer, colorectal cancer, thyroid cancer, esophageal squamous cell carcinoma, melanoma, prostate cancer and ovarian cancer, and promotes tumor progression (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . The crucial role of KMT5A in human cancer progression has triggered an interest in investigating the potential association between KMT5A and ccRCC. Whether KMT5A serves a role in ccRCC invasion and metastasis remains unknown.
The present study aimed to investigate the function role of KMT5A in ccRCC development progression. Firstly, the present study analyzed the expression of KMT5A and its clinical significance in the ccRCC tissue samples using transwell assays to evaluate the function of KMT5A in RCC cell migration and invasiveness in vitro. The relationship between KMT5A and CDH1 were detected in the cell line and ccRCC samples, and the association between the combination of KMT5A and CDH1 expression and patient overall survival (OS) time were analyzed. Transwell assays. For transwell invasion assays, matrigel (BD biosciences, Franklin Lakes, NJ, USA) was allowed to polymerize at the base of the top chamber of a 24-well transwell plate (8 µm, Corning Costar Corp, Corning, NY, USA) for 45 min at 37˚C. 786-O (SCR, shKMT5A and shKMT5A-RES) and ACHN (SCR, shKMT5A and shKMT5A-RES) cells (1x10 5 cells/well) were starved in serum-and growth factor-free medium for 24 h and added to the top chambers. The bottom chambers were filled serum-containing medium (10% fetal bovine serum, Gibco; Thermo Fisher Scientific, Inc.). Cultures were maintained for 48 h, and was followed by the removal of non-invading cells from the upper surface of the membrane with cotton swabs. Cells that had invaded were fixed in 4% paraformaldehyde and stained with 0.1% crystal violet for 15 min at room temperature.
KMT5A promotes metastasis of clear cell renal cell carcinoma through reducing cadherin-1 expression
Western blotting. The 786-O (SCR, shKMT5A#1 and #2) cells were lysed in RIPA buffer (Thermo Fisher Scientific, Inc.) supplemented with protease inhibitors (Thermo Fisher Scientific, Inc.). The protein concentration of each sample was measured by the BCA Protein sssay kit (Thermo Fisher Scientific, Inc.). Then 10 µg of protein lysed buffer were subjected to a 10% SDS-PAGE and transferred to a PVDF membrane (Millipore, MA, USA). Following blocking with 5% non-fat milk for 2 h at room temperature, membranes were incubated with specific primary antibody at 4˚C overnight (KMT5A: 1:2,000, Abcam, #ab3798, Cambridge, MA, USA; CDH1: 1:2,000, #14472, Cell Signaling Technology, Inc., Danvers, MA, USA; β-actin: 1:10,000, Thermo Fisher Scientific, Inc., #MA5-15739-HRP). Following washing with TBST three times, membranes were incubated with HRP-conjugated secondary antibody (1:5,000, Cell Signaling Technology, #7076, Inc., Danvers, MA, USA) for 1 h at room temperature. Then proteins were photographed using ECL detection reagents (Thermo Fisher Scientific, Inc.) and detected with a Bio-Rad GelDoc XR+ system (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Luciferase reporter assay. Dual Luciferase Report Assay were performed according to the manufacturer's protocol (Dual-Glo ® Luciferase assay system, #E2940, Promega Corporation, Madison, WI, USA). In brief, 0.6 µg luciferase reporter and were cotransfected along with 0.3 µg pCMV-lacZ (Promega Corporation) plasmid into the 786-O cells (SCR and shKMT5A). At 48 h following transfection, these cells were harvested and lysed in 1x reporter lysis buffer (Promega Corporation). Luciferase activities were determined with luciferase assay system (Promega Corporation) according to the manufacturer's protocol. The method of normalization was the Firefly comparison with Renilla luciferase activity.
Chromatin immunoprecipitation (CHIP) assay.
Chromatin immunoprecipitation was performed following a published protocol (24) . Antibody against KMT5A (Abcam) was used to immunoprecipitate sonicated chromatins prepared from 786-O cells. Five percent of each post-sonication sample was saved as the input control and pre-immune IgG was used for specificity control. DNA extracted from precipitated chromatins were quantitated using qrtPCR in triplicates with primers for CDH1 promoter (forward, 5'-GCA GGT CCC ATA ACC CAC CT-3'; and reverse, 5'-CAT AGA CGC GGT GAC CCT CT-3'). DNA extracted from saved input were quantitated in parallel (Ct Statistical analysis. Statistical analysis was performed with SPSS version 22.0 (IBM Corp., Armonk, NY, USA). The Kaplan-Meier analysis with log-rank test, Pearson's test, Student's t-test One-way ANOVA and Bonferroni's post-hoc test were used for compare the differences between the variables. P<0.05 was considered to indicate statistically significant differences.
Results
High KMT5A expression is associated with shorter OS time in ccRCC. Firstly, the KMT5A mRNA levels were detected in 20 ccRCC and paired adjacent renal tissue specimens from the First Hospital of Quanzhou Affiliated to Fujian Medical University. The KMT5A mRNA levels were significantly upregulated in the ccRCC tissues compared with those in the adjacent normal tissues (Fig. 1A) . Subsequently, the KMT5A expression levels in the postoperative tumor tissues obtained from 522 patients with ccRCC were analyzed. These samples were grouped according to the KMT5A mRNA level (high KMT5A group: The expression range from 500.9 to 1870.24, n=261 and low KMT5A group: The expression range from 150.65 to 500.8, n=261) and the association between that and the OS time of the patients was assessed using Kaplan-Meier analysis. The OS time was significantly poorer in the high-expression group compared with the low-expression group (Fig. 1B) . Together, these findings suggest that KMT5A serves a role in ccRCC development.
KMT5A knockdown hinders RCC cell migration and invasiveness.
In order to evaluate the function of KMT5A in RCC cell migration and invasiveness in vitro, ccRCC and papillary RCC cells with silenced KMT5A expression (786-O-shKMT5A and ACHN-shKMT5A) and their corresponding controls (786-O-SCR and ACHN-SCR) were used. Transwell assays were performed to assess the migration and invasion ability of the cells. The cells with silenced KMT5A expression displayed sharp declines in cell migration and invasiveness compared with the corresponding control groups, which was prevented by re-expression of KMT5A ( Fig. 2A-D ). These data demonstrate that KMT5A enhances RCC cell migration and invasiveness in vitro.
KMT5A downregulates CDH1 expression. In order to explore whether KMT5A activates EMT in order to promote ccRCC metastasis, the effect of KMT5A on CDH1, a central participating factor in EMT, was investigated. Firstly, the question of whether KMT5A decreases CDH1 protein levels in ccRCC cells was addressed. Western blot analysis was used to determine any effects on the CDH1 protein expression levels in the KMT5A-knockout and control cells, and revealed that knockdown of KMT5A expression markedly upregulated CDH1 protein levels in 786-O cells (Fig. 3A) . Next, the CDH1 mRNA levels were measured, demonstrating that the knockdown of KMT5A increased CDH1 transcription levels (P<0.01; Fig. 3B ). Furthermore, the luciferase reporter assay revealed that silencing KMT5A in 786-O cells led to the activation of CDH1 promoter activity (P<0.01; Fig. 3C ). Finally, the chromatin immunoprecipitation (ChIP) assay demonstrated that immunoprecipitation using an anti-KMT5A antibody on chromatin fragments from 786-O cells specifically enriched CDH1 promoter sequences (P<0.01; Fig. 3D ), indicating that Fig. 4A ). Furthermore, a negative correlation was revealed between the expression levels of KMT5A and CDH1 in the ccRCC samples (r=-0.6506; P<0.001; Fig. 4B ). The patients whose samples expressed high CDH1 levels had longer OS times compared with those whose samples expressed low levels (Fig. 4C ). The patients with high KMT5A and low CDH1 expression levels were associated with the shortest OS times, and those with low KMT5A and high CDH1 expression levels were associated with the longest (Fig. 4D) . The combination of KMT5A and CDH1 was demonstrated to be a promising independent prognostic indicator for OS time (P<0.001), more accurate than KMT5A or CDH1 alone.
Discussion
ccRCC is one of the most common types of kidney cancer worldwide, and is associated with poor prognosis owing to high rates of metastasis and recurrence (25) (26) (27) . The underlying molecular mechanism in ccRCC metastasis is not well known. Numerous studies have reported that the EMT is an important process in ccRCC cell metastasis (28) (29) (30) (31) . In the present study, supporting evidence was collected for the hypothesis that KMT5A enhances EMT through inhibiting CDH1 transcription levels, and consequently inducing ccRCC cells metastasis. Consistent with these findings, ccRCC patients with high KMT5A expression levels were associated with shorter OS time. Overall, KMT5A is identified as an important factor in ccRCC cell metastasis.
Previous studies demonstrated that KMT5A serves a vital role in tumor development and progression (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . To the best of our knowledge, the association between KMT5A and ccRCC has not been reported to date. In the present study, it was confirmed that the KMT5A expression level was significantly upregulated in ccRCC tissues compared with the adjacent normal tissues. Furthermore, ccRCC patients with KMT5A-high expression levels in their tumor tissue were revealed to be associated with shorter postoperative OS time. Together, these data suggest that KMT5A may be a novel target for ccRCC treatment.
The epithelial-mesenchymal transition (EMT) is considered to be the initial step in ccRCC metastasis (28) and CDH1 is a central factor in this mechanism (29) (30) (31) . At present, no studies have reported on the association between KMT5A and CDH1 in ccRCC, to the best of our knowledge. The results of the present study demonstrated that the knockdown of KMT5A expression inhibits the migration and invasiveness of ccRCC 786-O cells. In order to investigate the molecular mechanism underlying the promotional effects of KMT5A on ccRCC metastasis, the present investigated the relationship between KMT5A and CDH1. The knockdown of KMT5A expression in the 786-O cells upregulated CDH1 mRNA and protein levels. Furthermore, downregulation of KMT5A increased CDH1 promoter luciferase activity in 786-O cells. Finally, the ChIP assay revealed that endogenous KMT5A was associated with the CDH1 promoter in the ccRCC cells. Together, these findings indicate that KMT5A may be an important factor in ccRCC cell migration and invasion by inhibiting CDH1 transcription.
ccRCC is associated with a markedly poor prognosis due to high rates of metastasis and recurrence. At present, no biomarkers are available for ccRCC diagnosis and prediction. The present findings demonstrated that KMT5A expression level was significantly upregulated in ccRCC tissues compared with adjacent normal tissues. Patients with high KMT5A expression levels were revealed to be associated with shorter postoperative OS time. In agreement with the clinical results, in vitro experiments demonstrated that KMT5A enhances ccRCC cell migration and invasion by inhibiting CDH1 expression. Patients with ccRCC who exhibited high KMT5A and low CDH1 levels had the poorest prognosis, with the shortest OS time, and those with low KMT5A and high CDH1 expression had the best prognosis. The combination of KMT5A and CDH1 was confirmed to be an independent prognostic indicator for OS (P<0.001), which was more accurate than monitoring KMT5A or CDH1 expression alone. Consequently, KMT5A serves an important role in ccRCC development and progression, and it may be a novel target for ccRCC treatment and prevention.
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